Somatic mutations in the KEAP1 or NRF2 gene in cancer cells as well as other mutations that disrupt the binding of KEAP1 to NRF2 lead to aberrant NRF2 activation [60,62]. The gene discussed is NFE2L2; the disease is cancer.